Best of ESMO 2026 in JAPAN

Live and On-Demand

ライブ配信　2026年11月22日（日）

プログラム

2026.11.04時点

Lap			演題数	プレゼンター	ファシリテーター	ディスカッサント
9:00 - 9:05	5 min	**Opening Message**		**野村 基雄** 京都大学医学部附属病院		
9:05 - 9:35	30 min	**Gastrointestinal cancer 1（肝胆膵） | Presentation**	3 演題	**宗 英 一郎** 慶應義塾大学病院	**溢木 太郎** 国立がん研究センター東病院	
9:35 - 9:50	15 min	**Discussion, Q&A**				
		Abstract FPN LBA8 / Jian Zhou Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1)				
		Abstract FPN 3136RO / Andrew Oar Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial				
		Abstract FPN LBA83 / Eileen M. O'Reilly Seven-Valent mKRAS-specific Lymph Node Targeted Amphiphile Immunotherapy Versus Observation in Resected Pancreatic Ductal Adenocarcinoma (PDAC): the AMPLIFY-7P randomized Phase 2 study				
9:50 - 10:20	30 min	**Gastrointestinal cancer 2（消化管） | Presentation**	3 演題	**白石 和寛** 名古屋医療センター	**平田 賢郎** 慶應義塾大学病院	
10:20 - 10:35	15 min	**Discussion, Q&A**				
		Abstract FPN 2875O / Manish A Shah Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: the Phase 3 randomized KEYNOTE-975 study				
		Abstract FPN LBA31 / Hiroya Taniguchi Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: the pragmatic phase 3 PRABITAS trial				
		Abstract FPN LBA7 / Ruihua Xu CLARITY-Gastric 01 (CG-01): a Phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2) positive gastroesophageal carcinoma (GEC)				
10:35 - 10:55	20 min	**Gynecological cancer | Presentation**	2 演題	**長谷川 幸清** 埼玉医科大学国際医療センター	**温泉川 真由** がん研究会有明病院	
10:55 - 11:05	10 min	**Discussion, Q&A**				
		Abstract FPN LBA11 / Domenica Lorusso Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 Study				
		Abstract FPN LBA12 / Brian Slomovitz KEYNOTE-C93/GOG-3064/ENGOT-en15: Phase 3, Randomized, Open-Label Study of First-Line (1L) Pembrolizumab (Pembro) vs Carboplatin (C) + Paclitaxel (P) in Mismatch Repair-Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (a/rEC)				
11:05 - 11:25	20 min	**Others 1（頭頸部） | Presentation**	2 演題	**西條 憲** 東北大学	**野村 基雄** 京都大学医学部附属病院	
11:25 - 11:35	10 min	**Discussion, Q&A**				
		Abstract FPN LBA43 / Shao Dong Hong Tam-Peli versus chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): a multicenter, randomized, open-label, phase 3 study (TAISHAN-301)				
		Abstract FPN 1539RO / Paul L Swiecicki Amivantamab + pembrolizumab + carboplatin in first-line recurrent/metastatic head & neck squamous cell cancer (1L R/M HNSCC): Results from the phase 1b/2 OrigAMI-4 study				
11:35 - 11:40	5 min	*Break*				
11:40 - 12:10	30 min	**オンコロジーライブセミナー①** **共催：ギリアド・サイエンシズ株式会社** ADC製剤の進化とトロデルビ ～MBC治療のこれまでとこれから～		**【司会】 上野 貴之**（がん研究会有明病院） **【講師】 能澤 一樹**（名古屋市立大学大学院医学研究科）		
12:10 - 12:15	5 min	*Break*				
12:15 - 12:45	30 min	**オンコロジーライブセミナー②** **共催：エグザクトサイエンス株式会社** MCED（多がん種早期検出）検査の最新動向と臨床応用への展望		**【司会】 上野 誠**（神奈川県立がんセンター） **【講師】 坂東 英明**（国立がん研究センター東病院）		
12:45 - 13:15	30 min	**Lung cancer 1 | Presentation**	3 演題	**酒谷 俊雄** NTT東日本関東病院	**後藤 悌** 国立がん研究センター中央病院	
13:15 - 13:30	15 min	**Discussion, Q&A**				
		Abstract FPN LBA5 / Ferdinandos Skoulidis Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC				
		Abstract FPN LBA6 / Shun Lu Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results				
		Abstract FPN LBA66 / Caicun Zhou Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study				
13:30 - 13:50	20 min	**Lung cancer 2 | Presentation**	2 演題	**古田 恵** 北海道大学	**生島 弘彬** 東京大学病院	
13:50 - 14:00	10 min	**Discussion, Q&A**				
		Abstract FPN LBA3 / Jacob Sands Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial				
		Abstract FPN 3808O / Charles M. Rudin Tarlatamab in Previously Treated SCLC: Extended Follow-up of Overall Survival from the Phase 3 DeLLphi-304 Trial				
14:00 - 14:20	20 min	**Others 2（肉腫・他） | Presentation**	3 演題	**野村 基雄** (LBA10/LBA1) 京都大学医学部附属病院 **土橋 賢司** (LBA9) 九州大学病院	**土橋 賢司** 九州大学病院 **野村 基雄** 京都大学医学部附属病院	**西條 憲** 東北大学
14:20 - 14:35	15 min	**Discussion, Q&A**				
		Abstract FPN LBA10 / Gwenaëlle Gravis MOIO: Interim analyses of a Phase III Randomized Non Inferiority Trial Assessing Reduced Frequency Immune Checkpoint Inhibitors in Responding Patients with Advanced/Metastatic Cancer.				
		Abstract FPN LBA1 / Georgina Long INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)				
		Abstract FPN LBA9 / Lu Xie Risvutatug Rezetecan (Ris-Rez) versus Gemcitabine and Docetaxel (GD) in Heavily Pretreated Patients (pts) with Relapsed or Refractory (R/R) Osteosarcoma: Primary Results from the Phase 3 ARTEMIS-011 Study				
14:35 - 14:40	5 min	*Break*				
14:40 - 15:20	40 min	**オンコロジーライブセミナー③** **共催：日本イーライリリー株式会社** ホルモン受容体陽性HER2陰性乳癌　薬物療法の最新動向		**【司会】 渡邉 純一郎**（順天堂大学大学院医学研究科） **【講師】 原 文堅**（愛知県がんセンター）		
15:20 - 15:50	30 min	**Breast cancer 1 | Presentation**	3 演題	**酒井 瞳** 昭和医科大学	**渡邉 諭美** 近畿大学	
15:50 - 16:05	15 min	**Discussion, Q&A**				
		Abstract FPN 1RO / Kevin Kalinsky Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy				
		Abstract FPN LBA51 / Hope Rugo Results From KEYNOTE-B49: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (Pembro) vs Placebo (Pbo) Plus Chemotherapy (CT) in Participants (Pts) With HR+/HER2− Advanced Breast Cancer (ABC)				
		Abstract FPN LBA96 / Rebecca Dent First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts with brain metastases in TROPION-Breast02				
16:05 - 16:25	20 min	**Breast cancer 2 | Presentation**	3 演題	**能澤 一樹** 名古屋市立大学	**尾崎 由記範** がん研究会有明病院	
16:25 - 16:35	10 min	**Discussion, Q&A**				
		Abstract FPN LBA23 / Sara Hurvitz Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer				
		Abstract FPN LBA25 / Dennis Slamon Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes				
		Abstract FPN 542RO / Yukinori Ozaki Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1				
16:35 - 16:55	20 min	**Genitourinary cancer | Presentation**	3 演題	**竹村 弘司** がん研究会有明病院	**野村 基雄** 京都大学医学部附属病院	
16:55 - 17:05	10 min	**Discussion, Q&A**				
		Abstract FPN LBA2 / Thomas Powles Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial				
		Abstract FPN 3586O / Toni K. Choueiri First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: randomized open-label phase 3 LITESPARK-012 study				
		Abstract FPN 3587O / Daniel Y C Heng Final analysis of the phase 3 LITESPARK-011 study: belzutifan (bel) plus lenvatinib (len) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy				
17:05 - 17:10	5 min	**Closing**		**後藤 悌** 国立がん研究センター中央病院		